IQV IQVIA Holdings Inc

IQVIA Launches Orchestrated Customer Engagement

IQVIA (NYSE:IQV), a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, today announced the launch of a new commercial technology solution, Orchestrated Customer Engagement (OCE). This technology drives a new commercial model of orchestration, uniquely adapted for the life sciences industry, which connects marketing, sales and other functions, enabling them to more effectively collaborate with customers.

“Orchestrated customer engagement is a transformative technology for life sciences commercial operations,” said Michael Townsend, Research Manager, Life Sciences Business Systems Strategies, IDC Health Insights. “It can result in increased productivity, better alignment and communication between former silos in pharmaceutical commercial operations, higher customer satisfaction among HCPs and other stakeholders, and higher trust by HCPs through more relevant, timely and valued engagements.”

Orchestrated Customer Engagement, built on best-in-class technologies such as Salesforce.com, Mulesoft, Amazon Web Services, Heroku and others, provides seamless integration across a “platform of platforms.” The solution leverages IQVIA’s Ada™, artificial intelligence that gives users recommendations for next-best actions; Apollo™, an intuitive user interface; and Lexi™, an application program interface (API) layer to connect all applications and data using common language. Life sciences companies are able to implement OCE with IQVIA or with other providers certified within the Salesforce.com ecosystem.

“OCE is a major shift in the application of technology to bring a new category of enterprise software to the market,” said Tal Rosenberg, IQVIA’s senior vice president, Technology Solutions. “Orchestration combines multichannel marketing, sales force effectiveness and closed-loop marketing by integrating horizontal silos across a pharmaceutical enterprise generating unprecedented customer insights, aligning messaging with customer needs, and coordinating content delivery across multiple channels to multiple stakeholders.”

IQVIA is committed to developing innovative technology solutions that help life sciences converge functional silos, integrate processes, strengthen customer relationships, and more effectively anticipate and respond to market changes. Additional information about OCE is available on the IQVIA website.

Today’s announcement of the availability of Orchestrated Customer Engagement will culminate with a state-of-the-art event for industry executives, editors and analysts, at the Bellevue Hotel in Philadelphia, from 4:00 to 7:00 PM.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIA’s approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.IQVIA.com.

Click here to subscribe to Mobile Alerts for IQVIA.

EN
12/12/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IQVIA Holdings Inc

IQVIA Holdings Inc: 1 director

A director at IQVIA Holdings Inc sold 1,300 shares at 246.330USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

Moody's assigns Baa3 rating to IQVIA's new senior secured notes, Ba2 r...

Moody's Investors Service (Moody's) assigned Baa3 rating to the proposed US dollar-denominated senior secured notes, and Ba2 rating to the proposed senior unsecured notes of IQVIA Inc. ("IQVIA"). There are no changes to IQVIA's existing ratings, including the Ba1 corporate family rating (CFR), Ba1-P...

IQVIA HOLDINGS sees a downgrade to Slightly Negative on account of les...

The independent financial analyst theScreener just lowered the general evaluation of IQVIA HOLDINGS (US), active in the Health Care Providers industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date January 18, 2022, the closing price was US...

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2021 12 07

Freeport-McMoRan (FCX) is one of the best-positioned copper miners to benefit from the various megatrends pushing copper demand higher. Uniform Accounting highlights that the market is significantly mispricing the value of Freeport's production capabilities, signaling the potential for equity upside. With trends like the IoT and EVs driving stronger demand for precious metals, copper producers like Freeport are well positioned for a boost in profitability. Additionally, Freeport has the po...

Valens Research
  • Valens Research

IQV - Embedded Expectations Analysis - 2021 12 02

IQVIA Holdings (IQV) currently trades above corporate and historical averages relative to Uniform earnings, with a 28.2x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to recover to 62%, accompanied by 12% Uniform asset growth. Similarly, analysts expect Uniform ROA to improve to 58% by 2022, accompanied by 24% Uniform asset growth. If sustained going forward, these levels would imply a stock price closer to $414, representing significant potenti...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch